Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
Rhea-AI Summary
Moleculin (Nasdaq: MBRX) released a new CEO Corner segment featuring CEO Walter Klemp discussing progress in the pivotal MIRACLE adaptive Phase 3 study of Annamycin plus cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia.
The trial was designed with input from the U.S. FDA and begins with an initial cohort of 45 patients; after treatment of these patients an interim unblinding will assess safety and efficacy to inform the regulatory path. Enrollment and dosing are progressing as planned, with completion of treatment for the first 45 patients expected in the near term. The program builds on earlier MB-106 results where AnnAraC reportedly exceeded historical overall survival benchmarks.
Positive
- Adaptive Phase 3 design developed with U.S. FDA input
- Initial cohort size explicitly defined as 45 patients
- Planned interim unblinding to assess safety and efficacy
- Enrollment and dosing reported as progressing as planned
Negative
- No efficacy or safety results reported from the MIRACLE Phase 3 interim analysis yet
- Regulatory path depends on interim data from a small 45-patient cohort
Key Figures
Market Reality Check
Peers on Argus
MBRX showed a modest 0.51% gain while several biotech peers (e.g., LPTX +238.84%, MBIO +7.6%, KZIA +5.71%) also traded higher, but no peers appeared in the momentum scanner, indicating this move was not flagged as a sector-wide rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Warrant exercise financing | Negative | -44.3% | Inducement agreements for warrant exercise raising about $8.3M gross proceeds. |
| Feb 18 | Clinical trial update | Positive | +5.5% | Preliminary blinded 40% CRc rate in first 30 MIRACLE trial subjects. |
| Feb 17 | Patent allowance | Positive | +5.1% | Japan notice of allowance for liposomal Annamycin reconstitution patent. |
| Feb 13 | Investor outreach launch | Positive | +2.9% | Launch of CEO Corner platform to discuss strategy and clinical progress. |
| Feb 05 | Conference participation | Neutral | -6.5% | Announcement of participation in a Webull Corporate Connect webinar. |
Recent news flow often aligned with price moves, with positive clinical, patent, and communication updates followed by gains, while a financing-related warrant exercise coincided with a sharp decline and a neutral webinar headline saw a negative reaction.
Over the last month, Moleculin news has focused on financing, clinical progress, IP, and investor outreach. An $8.3 million warrant exercise on Feb 19, 2026 was followed by a large decline, contrasting with positive reactions to MIRACLE trial data and a Japanese patent allowance on Feb 18–17. Launch of the CEO Corner on Feb 13 and participation in a webinar on Feb 5 underscored a push in investor communications. Today’s CEO Corner segment continues that communication theme around MIRACLE trial progress.
Regulatory & Risk Context
An effective S-3 shelf dated Sep 19, 2025 registers up to 64,864,864 common shares issuable from Series F warrants. The company would receive cash proceeds only upon warrant exercise; full cash exercise of the registered warrants would yield gross proceeds of $35.7 million. The shares are registered for resale by selling stockholders, so Moleculin does not receive proceeds from their resale.
Market Pulse Summary
This announcement highlights Moleculin’s ongoing communication strategy around its pivotal MIRACLE Study, including an adaptive Phase 3 design with an initial 45-patient cohort and an interim unblinding to assess safety and efficacy. Recent history shows meaningful clinical data, IP expansion, and multiple warrant structures, including an active shelf for up to 64,864,864 shares and potential proceeds of $35.7 million. Investors may watch upcoming MIRACLE unblinding milestones and outcomes of the April 15, 2026 warrant-approval vote.
Key Terms
cytarabine medical
acute myeloid leukemia medical
phase 3 medical
AI-generated analysis. Not financial advice.
Access the Moleculin CEO Corner here
HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner is designed to provide investors and stakeholders with enhanced insight into the Company’s corporate developments, clinical progress and strategic initiatives.
As part of the segment, Mr. Klemp discussed progress on the Company’s pivotal MIRACLE Study evaluating Annamycin in combination with cytarabine (AnnAraC) for patients with relapsed or refractory Acute Myeloid Leukemia. Mr. Klemp explained that the adaptive Phase 3 trial was designed with input from the U.S. Food and Drug Administration and includes an initial cohort of 45 patients. After treatment of these patients is completed, the study will undergo an interim unblinding to evaluate safety and efficacy and help inform the most efficient regulatory path forward. Enrollment and dosing across clinical sites are progressing as planned, with completion of treatment for the first 45 patients expected in the near term. The study builds on encouraging results from the Company’s earlier MB-106 Study, in which AnnAraC demonstrated overall survival outcomes that exceeded historical benchmarks in this difficult-to-treat patient population.
Access the CEO Corner on the Company’s website here.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) and, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding the continued recruitment, treatment, and receipt of the unblinded data for the first 45 subjects of the MIRACLE clinical trial as described. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
FAQ
What did Moleculin (MBRX) announce about the MIRACLE Phase 3 study on March 11, 2026?
How is the MIRACLE trial designed and what role did the FDA play in MBRX's March 2026 update?
What happens after the first 45 patients are treated in the MBRX MIRACLE study?
Does Moleculin report any clinical results from the MIRACLE study in the March 11, 2026 update?
How does the MIRACLE study relate to Moleculin's prior MB-106 results referenced on March 11, 2026?
